BioMarin to Participate in Upcoming Virtual Investor Conference
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has announced that Brian Mueller, Executive Vice President and Chief Financial Officer, will participate in Morningstar's Management Behind the Moat Conference on September 30, 2020, at 1:00 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has announced that Brian Mueller, Executive Vice President and Chief Financial Officer, will participate in Morningstar's Management Behind the Moat Conference on September 30, 2020, at 1:00 PM ET. The conference will be accessible through a live audio webcast, which can be found on the company's investor relations website. An archived version will also be available for a limited time. BioMarin specializes in developing therapies for serious rare disorders and has six commercial products along with several candidates in its portfolio.
Details
News Market Reaction – BMRN
The recorded move for BMRN in the trading session of this news was -2.55%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN RAFAEL, Calif., Sept. 29, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Brian Mueller, Executive Vice President, Chief Financial Officer, will participate in Morningstar's Management Behind the Moat Conference on September 30, 2020 at 1:00pm ET. An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of six commercialized products and multiple clinical and pre-clinical product candidates.
For additional information, please visit www.biomarin.com. Information on BioMarin's website is not incorporated by reference into this press release.
Contacts: | |
Investors | Media |
Traci McCarty | Debra Charlesworth |
BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical Inc. |
(415) 455-7558 | (415) 455-7451 |
View original content to download multimedia:http://www.prnewswire.com/news-releases/biomarin-to-participate-in-upcoming-virtual-investor-conference-301139652.html
SOURCE BioMarin Pharmaceutical Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.